Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2303 vs MabThera plus CHOP in previously untreated CD20-positive DLBCL
CTR20182377Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Dec 2018; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20182377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182377.